A New Hope for a Devastating Disease: Hydrogen Sulfide in Parkinson’s Disease
- 446 Downloads
Hydrogen sulfide (H2S) has been regarded as the third gaseous transmitter alongside nitric oxide (NO) and carbon monoxide (CO). In mammalian brain, H2S is produced redundantly by four enzymatic pathways, implying its abundance in the organ. In physiological conditions, H2S has been found to induce the formation of long-term potential in neuronal cells by augmenting the activity of N-methyl-D-aspartate (NMDA) receptor. Likewise, it also actively takes part in the regulation of intracellular Ca2+ and pH homeostasis in both neuronal cells and glia cells. Intriguingly, emerging evidence indicates a connection of H2S with Parkinson’s disease. Specifically, the endogenous H2S level in the substantia nigra (SN) is significantly reduced along with 6-hydroxydopamine (6-OHDA) treatment in rats, while supplementation of H2S not only reverses 6-OHDA-induced neuronal loss but also attenuates the following disorders of movement, suggesting a protective effect of H2S in Parkinson’s disease (PD). Remarkably, the protective effect has been extensively demonstrated with various in vitro and in vivo PD models. These suggest that H2S may be a new hope for the treatment of PD. Further studies have shown that the protective effects can be ascribed to H2S-mediated anti-oxidation, anti-inflammation, anti-apoptosis, and pro-survival activity, which are also summarized in the review. Moreover, the progresses on the development of H2S donors are also conveyed with an emphasis on the treatment of PD. Nevertheless, one should bear in mind that the precise role of H2S in the pathogenesis of PD remains largely elusive. Therefore, more studies are warranted before turning the hope into a real therapy for PD.
KeywordsHydrogen sulfide Brain modulation Parkinson’s disease Anti-oxidation Protective effect H2S donors
Compliance with Ethical Standards
This work was supported by grants from NMRC/CIRG/1432/2015 and NUHSRO/2011/012/STB/B2B-08.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 10.Wu CHK (2013) The role of hydrogen sulphide in lung diseases. Bioscience Horizons 6:hzt009Google Scholar
- 45.Lu M, Zhao F-F, Tang J-J, Su C-J, Fan Y, Ding J-H, Bian J-S, Hu G (2012) The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels. Antioxid Redox Signal 17(6):849–859PubMedPubMedCentralCrossRefGoogle Scholar
- 56.Gong Q-H, Wang Q, Pan L-L, Liu X-H, Xin H, Zhu Y-Z (2011) S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF-κB pathway in rats. Brain Behav Immun 25(1):110–119PubMedCrossRefGoogle Scholar
- 68.Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, Zhao Y, Baskar R et al (2008) Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 117(18):2351–2360. doi: 10.1161/CIRCULATIONAHA.107.753467 PubMedCrossRefGoogle Scholar
- 71.Juman S, Nara Y, Yasui N, Negishi H, Okuda H, Takado N, Miki T (2016) Reduced production of hydrogen sulfide and sulfane sulfur due to low cystathionine beta-synthase levels in brain astrocytes of stroke-prone spontaneously hypertensive rats. Biol Pharm Bull 39(12):1932–1938. doi: 10.1248/bpb.b16-00334 PubMedCrossRefGoogle Scholar
- 74.Feng W, Teo XY, Novera W, Ramanujulu PM, Liang D, Huang D, Moore PK, Deng LW et al (2015) Discovery of new H2S releasing phosphordithioates and 2,3-dihydro-2-phenyl-2-sulfanylenebenzo[d][1,3,2]oxazaphospholes with improved antiproliferative activity. J Med Chem 58(16):6456–6480. doi: 10.1021/acs.jmedchem.5b00848 PubMedCrossRefGoogle Scholar
- 75.Yagdi E, Cerella C, Dicato M, Diederich M (2016) Garlic-derived natural polysulfanes as hydrogen sulfide donors: friend or foe? Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. doi: 10.1016/j.fct.2016.07.016
- 76.Tao M, Gao L, Pan J, Wang X (2014) Study on the inhibitory effect of allicin on human gastric cancer cell line SGC-7901 and its mechanism. African journal of traditional, complementary, and alternative medicines : AJTCAM / African Networks on Ethnomedicines 11(1):176–179Google Scholar
- 81.Mostafa DK, El Azhary NM, Nasra RA (2016) The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine. Can J Physiol Pharmacol 94(7):699–708. doi: 10.1139/cjpp-2015-0316 PubMedCrossRefGoogle Scholar
- 83.Liu H, Mao P, Wang J, Wang T, Xie CH (2015) Allicin protects PC12 cells against 6-OHDA-induced oxidative stress and mitochondrial dysfunction via regulating mitochondrial dynamics. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 36(3):966–979. doi: 10.1159/000430271 CrossRefGoogle Scholar
- 91.Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. The Cochrane database of systematic reviews 11:CD008454. doi: 10.1002/14651858.CD008454.pub2 Google Scholar
- 93.Hirose Y (2010) Clinical aspects of hydrogen sulfide poisoning. Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology 23(3):212–216Google Scholar